Canton Strategic Holdings Inc
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $168.1M
- Price
- $2.18
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.36%
- Volume
- 472.5K
About
Canton Strategic Holdings Inc., which was formerly known as Tharimmune, Inc. until its name change in February 2026, focuses on two primary areas. The company is committed to promoting the institutional integration of blockchain technology and fostering the digitization of financial markets, primarily by leveraging Canton Coin and offering support to the Canton network. In addition to its blockchain initiatives, the company is also deeply involved in pharmaceutical research and development. Its pipeline includes GV104, a buccal film technology designed to address respiratory and/or nervous system depression in military personnel and chemical incident responders, which has already finished its Phase 1 trial. Another significant project is GV023, an oral version of infliximab, engineered to resolve the key inconvenience of the standard intravenous treatment by eliminating the need for recurring infusions. Established in 2017, Canton Strategic Holdings Inc. is headquartered in Red Bank, New Jersey.
Quick stats
Shares outstanding77.1M
Computed float68.4M
Float / shares88.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001861657
AI Summary
AI-generated1/11
majorbullishearnings
Canton Strategic Holdings, Inc. Releases Second Quarter 2026 Financial and Operational Results
Canton Strategic reported its first operating revenue of $1.5 million in Q2 2026, driven by its Locking-as-a-Service (LaaS) offering and Super Validator operations on the Canton Network.
The company approved a $50 million share repurchase program and completed the sale of its legacy biotech subsidiary, Gravitas, while strengthening its board with three new directors.
Despite a net loss of $19.3 million—largely due to unrealized losses on digital assets—the company increased its cash position to $37.2 million and holds Canton Coin assets valued at over $523 million.
Red flags
- Gravitas subsidiary sold for unsecured promissory note rather than cash
- High net loss driven by volatile digital asset valuations ($23.7M unrealized loss)